<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02105012</url>
  </required_header>
  <id_info>
    <org_study_id>PT008001</org_study_id>
    <nct_id>NCT02105012</nct_id>
  </id_info>
  <brief_title>Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma</brief_title>
  <official_title>Randomized, Double-Blind, Chronic Dosing (4 Weeks), Four-Period, Five-Treatment, Incomplete Block, Cross-Over, Multi-Center Study to Assess the Efficacy and Safety of Four Doses of Budesonide Inhalation Aerosol (BD MDI, PT008) Relative to Placebo MDI in Adult Subjects With Mild to Moderate Persistent Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pearl Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pearl Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to assess the efficacy and safety of four doses of budesonide inhalation aerosol (BD
      MDI, PT008) relative to placebo MDI in adult subjects with mild to moderate persistent
      asthma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, chronic dosing (4 weeks), four-period, five-treatment,
      incomplete block, cross-over, multicenter study to assess the efficacy and safety of four
      doses of budesonide inhalation aerosol (BD MDI, PT008) relative to placebo MDI in adult
      subjects with mild to moderate persistent asthma.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2014</start_date>
  <completion_date type="Actual">September 4, 2015</completion_date>
  <primary_completion_date type="Actual">September 1, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Morning Pre-dose Trough Forced Expiratory Volume in 1 Second (FEV1) at the End of the Treatment Period</measure>
    <time_frame>Baseline to End of Treatment Period (Day 29 or Day 15 if Day 29 is missing)</time_frame>
    <description>Change from baseline in morning pre-dose trough Forced Expiratory Volume in 1 second (FEV1) at the end of the Treatment Period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Morning Pre-dose Diary Peak Expiratory Flow Rate (PEFR)</measure>
    <time_frame>Baseline to Last 7 Days of Treatment Period</time_frame>
    <description>Change From Baseline in Mean Morning Pre-dose Diary Peak Expiratory Flow Rate (PEFR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Evening Pre-dose Diary Peak Expiratory Flow Rate (PEFR)</measure>
    <time_frame>Baseline to Last 7 Days of Treatment Period</time_frame>
    <description>Change From Baseline in Mean Evening Pre-dose Diary Peak Expiratory Flow Rate (PEFR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Number of Puffs of Rescue Ventolin HFA</measure>
    <time_frame>Baseline to Last 7 Days of Treatment</time_frame>
    <description>Change from baseline in mean number of puffs of rescue Ventolin HFA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Asthma Control Questionnaire (ACQ-5) Score</measure>
    <time_frame>Baseline to End of Treatment Period (Day 29 or Day 15 if Day 29 is missing)</time_frame>
    <description>The ACQ-5 measures 5 symptoms (woken at night by symptoms, wake in the morning with symptoms, limitation of daily activities, shortness of breath, and wheeze). The scale is 0-6, where 0=minimum and 6=maximum</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">147</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>BD MDI 320 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Budesonide metered dose inhaler (BD MDI) 320 µg (PT008) administered as 2 inhalations BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BD MDI 160 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BD MDI 160 µg (PT008) administered as 2 inhalations BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BD MDI 80 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BD MDI 80 µg (PT008) administered as 2 inhalations BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BD MDI 40 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BD MDI 40 µg (PT008) administered as 2 inhalations BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo MDI</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo MDI administered as 2 inhalations BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BD MDI 320 µg</intervention_name>
    <description>Budesonide Inhalation Aerosol administered as 2 inhalations BID</description>
    <arm_group_label>BD MDI 320 µg</arm_group_label>
    <other_name>PT008</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BD MDI 160 µg</intervention_name>
    <description>Budesonide Inhalation Aerosol administered as 2 inhalations BID</description>
    <arm_group_label>BD MDI 160 µg</arm_group_label>
    <other_name>PT008</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BD MDI 80 µg</intervention_name>
    <description>Budesonide Inhalation Aerosol administered as 2 inhalations BID</description>
    <arm_group_label>BD MDI 80 µg</arm_group_label>
    <other_name>PT008</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BD MDI 40 µg</intervention_name>
    <description>Budesonide Inhalation Aerosol administered as 2 inhalations BID</description>
    <arm_group_label>BD MDI 40 µg</arm_group_label>
    <other_name>PT008</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo MDI</intervention_name>
    <description>Placebo MDI administered as 2 inhalations BID</description>
    <arm_group_label>Placebo MDI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 18 - 65 years of age

          -  Diagnosis of mild to moderate persistent asthma, diagnosed at least 6 months prior to
             screening

          -  Currently receiving treatment with a low to medium dose of an inhaled corticosteroid
             (ICS) OR a combination of controller medications for at least 4 weeks preceding
             screening

          -  Pre-albuterol FEV1 of &gt; 60% and &lt; 85% of predicted normal value

          -  Reversibility: Increase in FEV1 of ≥ 12% and ≥ 200 mL over the pre-albuterol FEV1
             within 30 - 60 minutes after the inhalation of 4 puffs of Ventolin hydrofluoroalkane
             (HFA)

          -  Asthma Symptom Criteria: Have required albuterol use on at least two of the last seven
             days and have an Asthma Control Questionnaire (ACQ) total score ≥ 1.5 prior to
             Randomization

        Exclusion Criteria:

          -  Life-Threatening Asthma: A subject must not have life-threatening asthma defined as a
             history of significant asthma episode(s) requiring intubation associated with
             hypercapnia, respiratory arrest, hypoxic seizures, or asthma-related syncopal
             episode(s) within the 12 months prior to screening

          -  Worsening of Asthma: A subject must not have experienced a worsening of asthma which
             involved an emergency department visit, hospitalization or use of oral/parenteral
             corticosteroids within 6 weeks of screening

          -  Intermittent, Seasonal, or Exercise-Induced Asthma Alone: Subjects with only
             intermittent, seasonal or exercise-induced asthma are excluded from participation in
             this study

          -  Concurrent Respiratory Disease

          -  Pregnant women or nursing mothers

          -  A current diagnosis of Chronic Obstructive Pulmonary Disease (COPD

          -  Current smokers or subjects with a &gt; 10 pack year history of cigarettes, cigars, or
             pipe smoking

          -  Respiratory tract infection within 6 weeks prior to Visit 1

          -  Subjects with documented myocardial infarction within a year from screening visit

          -  Clinically significant abnormal ECG

          -  Abnormal liver function tests defined as aspartate aminotransferase (AST), alanine
             aminotransferace (ALT), alkaline phosphatase or total bilirubin ≥ 1.5 times upper
             limit of normal on repeat testing

          -  Subjects who have cancer that has not been in complete remission for at least 5 years

          -  Drug Allergy: Subjects who have a history of hypersensitivity to any component of the
             metered-dose inhaler (MDI)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Dorinsky, MD, FCCP</last_name>
    <role>Study Director</role>
    <affiliation>Pearl Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pearl Therapeutics Study Site</name>
      <address>
        <city>Athens</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Study Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Study Site</name>
      <address>
        <city>Foley</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Study Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Study Site</name>
      <address>
        <city>Rolling Hills Estates</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Study Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Study Site</name>
      <address>
        <city>Stockton</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Study Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Study Site</name>
      <address>
        <city>Clermont</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Study Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Study Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Study Site</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Study Site</name>
      <address>
        <city>Saint Cloud</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Study Site</name>
      <address>
        <city>Sebring</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Study Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Study Site</name>
      <address>
        <city>Blue Island</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Study Site</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Study Site</name>
      <address>
        <city>Hazelwood</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Study Site</name>
      <address>
        <city>Skillman</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Study Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Study Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Study Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Study Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Study Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Study Site</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Study Site</name>
      <address>
        <city>Oregon</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Study Site</name>
      <address>
        <city>Sylvania</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Study Site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Study Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Study Site</name>
      <address>
        <city>Lake Oswego</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Study Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Study Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Study Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Study Site</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Study Site</name>
      <address>
        <city>Tullahoma</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Study Site</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Study Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Study Site</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Study Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Study Site</name>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2014</study_first_submitted>
  <study_first_submitted_qc>April 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2014</study_first_posted>
  <results_first_submitted>October 31, 2016</results_first_submitted>
  <results_first_submitted_qc>May 5, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 6, 2017</results_first_posted>
  <last_update_submitted>May 5, 2017</last_update_submitted>
  <last_update_submitted_qc>May 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mild</keyword>
  <keyword>moderate persistent</keyword>
  <keyword>Adult</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Conducted at 44 sites in the US from May 2015 to September 2015. Study participation maximum of 32 weeks.</recruitment_details>
      <pre_assignment_details>A Randomized, Double-Blind, Chronic Dosing (4 Weeks), Four-Period, Five-Treatment, Incomplete Block, Cross-Over, Multi-Center Study to Assess the Efficacy and Safety of Four Doses of Budesonide Inhalation Aerosol (BD MDI, PT008) Relative to Placebo MDI in Adult Subjects With Mild to Moderate Persistent Asthma</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>All Subjects</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="147"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>BD MDI 320 µg</title>
              <participants_list>
                <participants group_id="P1" count="124"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>BD MDI 160 µg</title>
              <participants_list>
                <participants group_id="P1" count="132"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>BD MDI 80 µg</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>BD MDI 40 µg</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Placebo MDI</title>
              <participants_list>
                <participants group_id="P1" count="127"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="114"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Specified Criteria</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Population</population>
      <group_list>
        <group group_id="B1">
          <title>All Subjects</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="147"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.7" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Morning Pre-dose Trough Forced Expiratory Volume in 1 Second (FEV1) at the End of the Treatment Period</title>
        <description>Change from baseline in morning pre-dose trough Forced Expiratory Volume in 1 second (FEV1) at the end of the Treatment Period.</description>
        <time_frame>Baseline to End of Treatment Period (Day 29 or Day 15 if Day 29 is missing)</time_frame>
        <population>Modified Intent to Treat Population (MITT)</population>
        <group_list>
          <group group_id="O1">
            <title>BD MDI 320 µg</title>
            <description>Budesonide (BD) Metered Dose Inhaler (MDI) 320 µg</description>
          </group>
          <group group_id="O2">
            <title>BD MDI 160 µg</title>
            <description>Budesonide (BD) Metered Dose Inhaler (MDI) 160 µg</description>
          </group>
          <group group_id="O3">
            <title>BD MDI 80 µg</title>
            <description>Budesonide (BD) Metered Dose Inhaler (MDI) 80 µg</description>
          </group>
          <group group_id="O4">
            <title>BD MDI 40 µg</title>
            <description>Budesonide (BD) Metered Dose Inhaler (MDI) 40 µg</description>
          </group>
          <group group_id="O5">
            <title>Placebo MDI</title>
            <description>Placebo MDI.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Morning Pre-dose Trough Forced Expiratory Volume in 1 Second (FEV1) at the End of the Treatment Period</title>
          <description>Change from baseline in morning pre-dose trough Forced Expiratory Volume in 1 second (FEV1) at the end of the Treatment Period.</description>
          <population>Modified Intent to Treat Population (MITT)</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="109"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="56"/>
                <count group_id="O5" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.002" lower_limit="-0.036" upper_limit="0.033"/>
                    <measurement group_id="O2" value="-0.001" lower_limit="-0.035" upper_limit="0.033"/>
                    <measurement group_id="O3" value="-0.034" lower_limit="-0.081" upper_limit="0.014"/>
                    <measurement group_id="O4" value="-0.031" lower_limit="-0.079" upper_limit="0.016"/>
                    <measurement group_id="O5" value="-0.116" lower_limit="-0.150" upper_limit="-0.082"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Morning Pre-dose Diary Peak Expiratory Flow Rate (PEFR)</title>
        <description>Change From Baseline in Mean Morning Pre-dose Diary Peak Expiratory Flow Rate (PEFR)</description>
        <time_frame>Baseline to Last 7 Days of Treatment Period</time_frame>
        <population>MITT</population>
        <group_list>
          <group group_id="O1">
            <title>BD MDI 320 µg</title>
            <description>Budesonide (BD) Metered Dose Inhaler (MDI) 320 µg</description>
          </group>
          <group group_id="O2">
            <title>BD MDI 160 µg</title>
            <description>Budesonide (BD) Metered Dose Inhaler (MDI) 160 µg</description>
          </group>
          <group group_id="O3">
            <title>BD MDI 80 µg</title>
            <description>Budesonide (BD) Metered Dose Inhaler (MDI) 80 µg</description>
          </group>
          <group group_id="O4">
            <title>BD MDI 40 µg</title>
            <description>Budesonide (BD) Metered Dose Inhaler (MDI) 40 µg</description>
          </group>
          <group group_id="O5">
            <title>Placebo MDI</title>
            <description>Placebo MDI.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Morning Pre-dose Diary Peak Expiratory Flow Rate (PEFR)</title>
          <description>Change From Baseline in Mean Morning Pre-dose Diary Peak Expiratory Flow Rate (PEFR)</description>
          <population>MITT</population>
          <units>Liters/min</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.802" lower_limit="-17.937" upper_limit="6.333"/>
                    <measurement group_id="O2" value="-7.461" lower_limit="-19.536" upper_limit="4.614"/>
                    <measurement group_id="O3" value="-9.992" lower_limit="-24.293" upper_limit="4.309"/>
                    <measurement group_id="O4" value="-5.653" lower_limit="-20.320" upper_limit="9.014"/>
                    <measurement group_id="O5" value="-29.933" lower_limit="-42.019" upper_limit="-17.847"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Evening Pre-dose Diary Peak Expiratory Flow Rate (PEFR)</title>
        <description>Change From Baseline in Mean Evening Pre-dose Diary Peak Expiratory Flow Rate (PEFR)</description>
        <time_frame>Baseline to Last 7 Days of Treatment Period</time_frame>
        <population>MITT</population>
        <group_list>
          <group group_id="O1">
            <title>BD MDI 320 µg</title>
            <description>Budesonide (BD) Metered Dose Inhaler (MDI) 320 µg</description>
          </group>
          <group group_id="O2">
            <title>BD MDI 160 µg</title>
            <description>Budesonide (BD) Metered Dose Inhaler (MDI) 160 µg</description>
          </group>
          <group group_id="O3">
            <title>BD MDI 80 µg</title>
            <description>Budesonide (BD) Metered Dose Inhaler (MDI) 80 µg</description>
          </group>
          <group group_id="O4">
            <title>BD MDI 40 µg</title>
            <description>Budesonide (BD) Metered Dose Inhaler (MDI) 40 µg</description>
          </group>
          <group group_id="O5">
            <title>Placebo MDI</title>
            <description>Placebo MDI.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Evening Pre-dose Diary Peak Expiratory Flow Rate (PEFR)</title>
          <description>Change From Baseline in Mean Evening Pre-dose Diary Peak Expiratory Flow Rate (PEFR)</description>
          <population>MITT</population>
          <units>Liters/min</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="52"/>
                <count group_id="O5" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.345" lower_limit="-18.394" upper_limit="3.703"/>
                    <measurement group_id="O2" value="-11.791" lower_limit="-22.737" upper_limit="-0.844"/>
                    <measurement group_id="O3" value="-14.403" lower_limit="-28.118" upper_limit="-0.688"/>
                    <measurement group_id="O4" value="-1.896" lower_limit="-15.585" upper_limit="11.793"/>
                    <measurement group_id="O5" value="-32.807" lower_limit="-43.712" upper_limit="-21.902"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Number of Puffs of Rescue Ventolin HFA</title>
        <description>Change from baseline in mean number of puffs of rescue Ventolin HFA</description>
        <time_frame>Baseline to Last 7 Days of Treatment</time_frame>
        <population>MITT</population>
        <group_list>
          <group group_id="O1">
            <title>BD MDI 320 µg</title>
            <description>Budesonide (BD) Metered Dose Inhaler (MDI) 320 µg</description>
          </group>
          <group group_id="O2">
            <title>BD MDI 160 µg</title>
            <description>Budesonide (BD) Metered Dose Inhaler (MDI) 160 µg</description>
          </group>
          <group group_id="O3">
            <title>BD MDI 80 µg</title>
            <description>Budesonide (BD) Metered Dose Inhaler (MDI) 80 µg</description>
          </group>
          <group group_id="O4">
            <title>BD MDI 40 µg</title>
            <description>Budesonide (BD) Metered Dose Inhaler (MDI) 40 µg</description>
          </group>
          <group group_id="O5">
            <title>Placebo MDI</title>
            <description>Placebo MDI.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Number of Puffs of Rescue Ventolin HFA</title>
          <description>Change from baseline in mean number of puffs of rescue Ventolin HFA</description>
          <population>MITT</population>
          <units>Puffs/Day</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="56"/>
                <count group_id="O5" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.140" lower_limit="-0.531" upper_limit="0.251"/>
                    <measurement group_id="O2" value="-0.268" lower_limit="-0.654" upper_limit="0.119"/>
                    <measurement group_id="O3" value="-0.312" lower_limit="-0.810" upper_limit="0.186"/>
                    <measurement group_id="O4" value="-0.095" lower_limit="-0.592" upper_limit="0.402"/>
                    <measurement group_id="O5" value="0.606" lower_limit="0.218" upper_limit="0.994"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Asthma Control Questionnaire (ACQ-5) Score</title>
        <description>The ACQ-5 measures 5 symptoms (woken at night by symptoms, wake in the morning with symptoms, limitation of daily activities, shortness of breath, and wheeze). The scale is 0-6, where 0=minimum and 6=maximum</description>
        <time_frame>Baseline to End of Treatment Period (Day 29 or Day 15 if Day 29 is missing)</time_frame>
        <population>MITT</population>
        <group_list>
          <group group_id="O1">
            <title>BD MDI 320 µg</title>
            <description>Budesonide (BD) Metered Dose Inhaler (MDI) 320 µg</description>
          </group>
          <group group_id="O2">
            <title>BD MDI 160 µg</title>
            <description>Budesonide (BD) Metered Dose Inhaler (MDI) 160 µg</description>
          </group>
          <group group_id="O3">
            <title>BD MDI 80 µg</title>
            <description>Budesonide (BD) Metered Dose Inhaler (MDI) 80 µg</description>
          </group>
          <group group_id="O4">
            <title>BD MDI 40 µg</title>
            <description>Budesonide (BD) Metered Dose Inhaler (MDI) 40 µg</description>
          </group>
          <group group_id="O5">
            <title>Placebo MDI</title>
            <description>Placebo MDI.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Asthma Control Questionnaire (ACQ-5) Score</title>
          <description>The ACQ-5 measures 5 symptoms (woken at night by symptoms, wake in the morning with symptoms, limitation of daily activities, shortness of breath, and wheeze). The scale is 0-6, where 0=minimum and 6=maximum</description>
          <population>MITT</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="57"/>
                <count group_id="O5" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.575" lower_limit="-0.730" upper_limit="-0.420"/>
                    <measurement group_id="O2" value="-0.565" lower_limit="-0.717" upper_limit="-0.412"/>
                    <measurement group_id="O3" value="-0.515" lower_limit="-0.714" upper_limit="-0.317"/>
                    <measurement group_id="O4" value="-0.407" lower_limit="-0.605" upper_limit="-0.209"/>
                    <measurement group_id="O5" value="-0.100" lower_limit="-0.252" upper_limit="0.052"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs were recorded from the time subjects received their first dose of study medication, during the entire study period, and up to 14 days from the date of the last study medication dose.</time_frame>
      <desc>The Safety population was defined as all subjects who were randomized to treatment and received at least 1 dose of the study treatment. Subjects in the Safety population were analyzed according to the treatment received.</desc>
      <group_list>
        <group group_id="E1">
          <title>BD MDI 320 µg</title>
          <description>Budesonide (BD) Metered Dose Inhaler (MDI) 320 µg</description>
        </group>
        <group group_id="E2">
          <title>BD MDI 160 µg</title>
          <description>Budesonide (BD) Metered Dose Inhaler (MDI) 160 µg</description>
        </group>
        <group group_id="E3">
          <title>BD MDI 80 µg</title>
          <description>Budesonide (BD) Metered Dose Inhaler (MDI) 80 µg</description>
        </group>
        <group group_id="E4">
          <title>BD MDI 40 µg</title>
          <description>Budesonide (BD) Metered Dose Inhaler (MDI) 40 µg</description>
        </group>
        <group group_id="E5">
          <title>Placebo MDI</title>
          <description>Placebo MDI.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="124"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="124"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="132"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent its opinions, or the opinions of the publication committee, if these differ with the proposed publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Paul Dorinsky, MD, FCCP</name_or_title>
      <organization>Pearl Therapeutics Inc.</organization>
      <phone>650-305-2600</phone>
      <email>pdorinsky@pearltherapeutics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

